TKNO — Alpha Teknova, Inc. Stock Price, Chart & AI Report

Positive Mar 11, 2025 • 23:00 UTC GlobeNewswire Inc. • Clear® Verified

Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies

Teknova and Pluristyx are collaborating to produce and commercialize Pluristyx's PluriFreeze cryopreservation system, which is designed to simplify the scale-up process for companies working to bring allogeneic cell therapies to market.

TKNO cell therapy cryopreservation manufacturing collaboration

Sentiment note

Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, and the collaboration with Pluristyx will enable wider customer access to their PluriFreeze product line.

Positive Jul 17, 2024 • 01:37 UTC Investing.com • Investing.Com

Telegraph Hill Partners buys $15m of Alpha Teknova shares at $1.24 each - Investing.com

Telegraph Hill Partners, a major shareholder in Alpha Teknova, Inc., has increased its stake in the company through a private placement, purchasing shares worth approximately $15 million at $1.24 per share. This transaction reflects a positive outlook from Telegraph Hill Partners on Alpha Teknova's future prospects.

TKNO Alpha Teknova Telegraph Hill Partners private placement investment

Sentiment note

The article indicates that Telegraph Hill Partners, a significant shareholder, has increased its stake in Alpha Teknova through a $15 million private placement, suggesting a positive outlook on the company's future.

Unknown Jun 24, 2024 • 13:35 UTC Zacks Investment Research • Zacks Equity Research

After Plunging -24.59% in 4 Weeks, Here's Why the Trend Might Reverse for Alpha Teknova (TKNO)

Alpha Teknova (TKNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

TKNO

Unknown Jun 6, 2024 • 16:00 UTC Zacks Investment Research • Zacks Equity Research

Alpha Teknova (TKNO) Upgraded to Buy: What Does It Mean for the Stock?

Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

TKNO

Unknown May 13, 2024 • 20:01 UTC GlobeNewswire Inc. • Alpha Teknova, Inc.

Teknova Reports First Quarter 2024 Financial Results

First quarter 2024 total revenue was $9.3 million, up 2% from prior yearLaunch of Build-Tek™ Custom ConfiguratorCompany reaffirms 2024 revenue guidance of $35-38 million

TKNO Earnings Releases and Operating Results

Unknown May 7, 2024 • 14:00 UTC GlobeNewswire Inc. • Alpha Teknova, Inc.

Teknova Launches Proprietary Build-Tek™ Solutions Custom Configurator and Latest AAV-Tek™ Product to Further Accelerate Novel Therapy Development

First-of-its-kind custom configurator – available today – gives scientists access to high quality, customizable buffers in small volumes for use in early-stage experiments, all with exceptionally short turnaround times

TKNO Product / Services Announcement

Unknown Apr 29, 2024 • 20:01 UTC GlobeNewswire Inc. • Alpha Teknova, Inc.

Teknova to Report First Quarter 2024 Financial Results on May 13, 2024

HOLLISTER, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, following the close of market.

TKNO Conference Calls/ Webcasts

Unknown Apr 24, 2024 • 13:35 UTC Zacks Investment Research • Zacks Equity Research

Down -28.04% in 4 Weeks, Here's Why Alpha Teknova (TKNO) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Alpha Teknova (TKNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

TKNO

Unknown Mar 11, 2024 • 20:01 UTC GlobeNewswire Inc. • Alpha Teknova, Inc.

Teknova Reports Fourth Quarter and Full Year 2023 Financial Results

Full year 2023 total revenue was $36.7 million, down 11% year-over-yearAchieved 36% annual growth in the number of Clinical Solutions customers in 2023Company provides 2024 revenue guidance of $35-38 million

TKNO Calendar of Events Earnings Releases and Operating Results Conference Calls/ Webcasts

Unknown Feb 21, 2024 • 21:01 UTC GlobeNewswire Inc. • Alpha Teknova, Inc.

Teknova to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

Teknova announces plans to issue fourth quarter and full year 2023 earnings report on March 11, 2024.

TKNO Calendar of Events Conference Calls/ Webcasts

Unknown Nov 9, 2023 • 21:01 UTC GlobeNewswire Inc. • Alpha Teknova, Inc.

Teknova Reports Third Quarter 2023 Financial Results

Teknova today announced financial results for the third quarter ended September 30, 2023.

TKNO Earnings Releases and Operating Results

Unknown Oct 26, 2023 • 12:00 UTC GlobeNewswire Inc. • Alpha Teknova, Inc.

Teknova to Report Third Quarter 2023 Financial Results on November 9, 2023

Teknova today announced that the Company will report its financial results for the third quarter on Thursday, November 9, 2023, following close of market.

TKNO Conference Calls/ Webcasts